Plant Name: Helichrysum subulifolium
Taxonomic Information:
Plant ID: NPO921
Plant Latin Name: Helichrysum subulifolium
Taxonomy Genus: Helichrysum
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ACHE; | |
| CLK2; GSK3B; CAMK2A; CAMK1D; JAK3; CAMKK2; PRKCQ; PDGFRA; GRK5; SGK2; RET; MARK4; STK3; CSNK1A1; SIK2; ROCK2; TAOK1; IKBKE; DYRK1B; TYRO3; FGFR1; FLT1; TBK1; ALK; CDK6; ROS1; JAK2; MAP4K4; BTK; LRRK2; CDK8; LTK; MAPK10; HCK; MARK3; ACVR1; PTK2; DYRK1A; MAP3K10; PRKX; TNK2; MELK; | |
| ALOX12; NOX4; APEX1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Protein Kinase | CLK2 | Dual specificity protein kinase CLK2 | P49760 | CHEMBL4225 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CAMK2A | CaM kinase II alpha | Q9UQM7 | CHEMBL4147 |
| Protein Kinase | CAMK1D | CaM kinase I delta | Q8IU85 | CHEMBL5073 |
| Protein Kinase | JAK3 | Tyrosine-protein kinase JAK3 | P52333 | CHEMBL2148 |
| Protein Kinase | CAMKK2 | CaM-kinase kinase beta | Q96RR4 | CHEMBL5284 |
| Protein Kinase | PRKCQ | Protein kinase C theta | Q04759 | CHEMBL3920 |
| Protein Kinase | PDGFRA | Platelet-derived growth factor receptor alpha | P16234 | CHEMBL2007 |
| Protein Kinase | GRK5 | G protein-coupled receptor kinase 5 | P34947 | CHEMBL5678 |
| Protein Kinase | SGK2 | Serine/threonine-protein kinase Sgk2 | Q9HBY8 | CHEMBL5794 |
| Protein Kinase | RET | Tyrosine-protein kinase receptor RET | P07949 | CHEMBL2041 |
| Protein Kinase | MARK4 | MAP/microtubule affinity-regulating kinase 4 | Q96L34 | CHEMBL5754 |
| Protein Kinase | STK3 | Serine/threonine-protein kinase MST2 | Q13188 | CHEMBL4708 |
| Protein Kinase | CSNK1A1 | Casein kinase I alpha | P48729 | CHEMBL2793 |
| Protein Kinase | SIK2 | Serine/threonine-protein kinase SIK2 | Q9H0K1 | CHEMBL5699 |
| Protein Kinase | ROCK2 | Rho-associated protein kinase 2 | O75116 | CHEMBL2973 |
| Protein Kinase | TAOK1 | Serine/threonine-protein kinase TAO1 | Q7L7X3 | CHEMBL5261 |
| Protein Kinase | IKBKE | Inhibitor of nuclear factor kappa B kinase epsilon subunit | Q14164 | CHEMBL3529 |
| Protein Kinase | DYRK1B | Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Q9Y463 | CHEMBL5543 |
| Protein Kinase | TYRO3 | Tyrosine-protein kinase receptor TYRO3 | Q06418 | CHEMBL5314 |
| Protein Kinase | FGFR1 | Fibroblast growth factor receptor 1 | P11362 | CHEMBL3650 |
| Protein Kinase | FLT1 | Vascular endothelial growth factor receptor 1 | P17948 | CHEMBL1868 |
| Protein Kinase | TBK1 | Serine/threonine-protein kinase TBK1 | Q9UHD2 | CHEMBL5408 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | ROS1 | Proto-oncogene tyrosine-protein kinase ROS | P08922 | CHEMBL5568 |
| Protein Kinase | JAK2 | Tyrosine-protein kinase JAK2 | O60674 | CHEMBL2971 |
| Protein Kinase | MAP4K4 | Mitogen-activated protein kinase kinase kinase kinase 4 | O95819 | CHEMBL6166 |
| Protein Kinase | BTK | Tyrosine-protein kinase BTK | Q06187 | CHEMBL5251 |
| Protein Kinase | LRRK2 | Leucine-rich repeat serine/threonine-protein kinase 2 | Q5S007 | CHEMBL1075104 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | LTK | Leukocyte tyrosine kinase receptor | P29376 | CHEMBL5627 |
| Protein Kinase | MAPK10 | c-Jun N-terminal kinase 3 | P53779 | CHEMBL2637 |
| Protein Kinase | HCK | Tyrosine-protein kinase HCK | P08631 | CHEMBL3234 |
| Protein Kinase | MARK3 | Serine/threonine-protein kinase c-TAK1 | P27448 | CHEMBL5600 |
| Protein Kinase | ACVR1 | Activin receptor type-1 | Q04771 | CHEMBL5903 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
| Protein Kinase | MAP3K10 | Mitogen-activated protein kinase kinase kinase 10 | Q02779 | CHEMBL2873 |
| Protein Kinase | PRKX | Serine/threonine-protein kinase PRKX | P51817 | CHEMBL5818 |
| Protein Kinase | TNK2 | Tyrosine kinase non-receptor protein 2 | Q07912 | CHEMBL4599 |
| Protein Kinase | MELK | Maternal embryonic leucine zipper kinase | Q14680 | CHEMBL4578 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004715; non-membrane spanning protein tyrosine kinase activity | 3.211E-13 | 1.128E-10 | BTK, DYRK1A, HCK, JAK2, JAK3, MELK, PTK2, TNK2 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.577E-11 | 4.705E-09 | BTK, HCK, JAK2, JAK3, PTK2, ROS1, TNK2 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 5.161E-09 | 9.524E-07 | ACVR1, ALOX12, CAMK1D, FGFR1, FLT1, JAK2, NOX4, PDGFRA, PTK2, RET, ROCK2 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 6.570E-09 | 1.163E-06 | ACVR1, ALOX12, CAMK1D, GRK5, GSK3B, HCK, JAK2, JAK3, LRRK2, LTK, MAP4K4, PRKCQ, PTK2, TYRO3 |
| CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 1.805E-08 | 2.828E-06 | BTK, HCK, JAK2, JAK3, PTK2, TNK2 |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 4.910E-07 | 6.724E-05 | FGFR1, FLT1, JAK2, PDGFRA, PTK2 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 8.929E-43 | 2.430E-39 | ACVR1, ALK, BTK, CAMK1D, CAMK2A, CAMKK2, CDK6, CDK8, CLK2, CSNK1A1, DYRK1A, DYRK1B, FGFR1, FLT1, GRK5, GSK3B, HCK, IKBKE, JAK2, JAK3, LRRK2, LTK, MAP3K10, MAP4K4, MAPK10, MARK3, MARK4, MELK, PDGFRA, PRKCQ, PRKX, PTK2, RET, ROCK2, ROS1, SGK2, SIK2, STK3, TAOK1, TBK1, TNK2, TYRO3 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.300E-06 | 1.736E-04 | CAMK1D, CAMK2A, GSK3B, JAK2, LTK, MAP3K10, MELK, NOX4, RET, STK3 |
| MF | GO:0098772; molecular function regulator | GO:0005088; Ras guanyl-nucleotide exchange factor activity | 1.896E-06 | 2.472E-04 | CAMK2A, FGFR1, JAK2, JAK3, PDGFRA, PTK2, RET |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.041E-06 | 3.895E-04 | ACHE, ACVR1, ALK, BTK, CAMK2A, CLK2, DYRK1A, FGFR1, JAK2, LRRK2, MAP3K10, PDGFRA, STK3, TBK1, TNK2 |
| CC | GO:0044464; cell part | GO:0005737; cytoplasm | 4.723E-06 | 5.910E-04 | ALOX12, APEX1, BTK, CAMK1D, CAMK2A, CAMKK2, CDK6, GRK5, GSK3B, IKBKE, JAK2, LRRK2, MAP3K10, MAP4K4, MAPK10, MELK, PDGFRA, PRKX, PTK2, SIK2, STK3, TAOK1, TBK1, TNK2 |
| BP | GO:0032501; multicellular organismal process | GO:0048731; system development | 4.817E-06 | 5.994E-04 | ACHE, ACVR1, CAMK2A, DYRK1A, FGFR1, MARK4, PDGFRA, RET, STK3, TAOK1 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 5.480E-06 | 6.780E-04 | ALOX12, CDK6, FGFR1, FLT1, GRK5, HCK, JAK2, JAK3, PDGFRA, PRKCQ, PTK2 |
| BP | GO:0008152; metabolic process | GO:0010468; regulation of gene expression | 1.568E-05 | 1.751E-03 | ACVR1, ALK, APEX1, BTK, CAMK1D, CAMK2A, CAMKK2, CDK6, CDK8, CLK2, DYRK1A, DYRK1B, FGFR1, GSK3B, HCK, JAK2, LRRK2, MAP3K10, MAPK10, PRKCQ, RET, ROCK2, ROS1, STK3, TBK1 |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 1.891E-05 | 2.090E-03 | CAMK2A, CDK6, DYRK1A, GSK3B, LRRK2, MAP3K10, MAP4K4, STK3, TAOK1 |
| BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 1.995E-05 | 2.183E-03 | ACVR1, APEX1, BTK, CDK6, FLT1, GSK3B, LRRK2, LTK, NOX4, RET, ROCK2, SIK2 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 2.185E-05 | 2.379E-03 | ALOX12, BTK, CAMK2A, CAMKK2, CDK6, CSNK1A1, FGFR1, GRK5, GSK3B, HCK, IKBKE, JAK2, JAK3, LRRK2, MAPK10, MARK3, MARK4, PRKCQ, PTK2, RET, ROCK2, SGK2, STK3, TAOK1, TBK1 |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 2.226E-05 | 2.411E-03 | ALK, LRRK2, MAP3K10, MAPK10, TAOK1 |
| CC | GO:0043226; organelle | GO:0005634; nucleus | 2.897E-05 | 3.093E-03 | ACHE, APEX1, BTK, CAMK1D, CAMK2A, CAMKK2, CDK6, CDK8, CLK2, DYRK1A, DYRK1B, GSK3B, IKBKE, JAK2, LRRK2, MAPK10, MELK, NOX4, PDGFRA, PRKX, PTK2, ROCK2, SIK2, STK3, TNK2, TYRO3 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.985E-05 | 3.171E-03 | FGFR1, NOX4, PDGFRA, PTK2, STK3 |
| BP | GO:0022610; biological adhesion | GO:0045785; positive regulation of cell adhesion | 3.350E-05 | 3.507E-03 | ALOX12, CDK6, GSK3B, JAK2, JAK3, PRKCQ, RET |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 4.906E-05 | 4.968E-03 | FLT1, PDGFRA, PTK2 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 5.476E-05 | 5.445E-03 | DYRK1A, GSK3B, MAPK10, PDGFRA, ROCK2, TYRO3 |
| BP | GO:0009987; cellular process | GO:0010543; regulation of platelet activation | 5.973E-05 | 5.859E-03 | ALOX12, PDGFRA, PRKCQ |
| BP | GO:0065007; biological regulation | GO:0010863; positive regulation of phospholipase C activity | 6.559E-05 | 6.376E-03 | FGFR1, FLT1, PDGFRA |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 7.015E-05 | 6.789E-03 | ACVR1, CAMK1D, HCK, JAK3, NOX4, PRKCQ, TBK1 |
| BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 1.006E-04 | 9.481E-03 | PRKCQ, PTK2, TAOK1 |
| BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 1.047E-04 | 9.747E-03 | CDK6, GSK3B, PTK2, ROCK2 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 6.366E-17 | 2.949E-14 | CAMK1D, CAMK2A, CAMKK2, CSNK1A1, DYRK1A, GSK3B, IKBKE, LRRK2, MAP3K10, PRKCQ, PRKX, SGK2, TBK1 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.732E-13 | 6.617E-11 | ACVR1, CAMK1D, CAMK2A, CAMKK2, DYRK1A, GSK3B, LRRK2, MAP3K10, TBK1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 6.928E-08 | 4.226E-06 | PDGFRA, GSK3B, CDK6, FLT1, JAK2, SGK2, JAK3, PTK2, FGFR1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 2.469E-08 | 3.013E-06 | GSK3B, TBK1, CDK6, PRKCQ, JAK2, JAK3, IKBKE |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 2.196E-07 | 8.930E-06 | GSK3B, HCK, GRK5, ROCK2, JAK2, JAK3, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.030E-06 | 9.242E-05 | RET, MAPK10, PDGFRA, GSK3B, CDK6, ROCK2, PTK2, FGFR1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 6.593E-06 | 1.609E-04 | MAPK10, PDGFRA, GSK3B, FLT1, ROCK2, PTK2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04310 | Wnt signaling pathway | 1.823E-05 | 3.064E-04 | MAPK10, GSK3B, ROCK2, CSNK1A1, CAMK2A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 2.475E-05 | 3.354E-04 | MAPK10, PDGFRA, TAOK1, MAP4K4, FGFR1, STK3 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.823E-05 | 3.064E-04 | ACVR1, GSK3B, JAK2, JAK3, FGFR1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 2.009E-05 | 3.064E-04 | MAPK10, PRKCQ, JAK2, CAMKK2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 4.966E-05 | 5.508E-04 | MAPK10, GSK3B, TBK1, JAK2, IKBKE |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 4.741E-05 | 5.508E-04 | MAPK10, GSK3B, CAMK2A, PTK2 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.553E-05 | 7.679E-04 | MAPK10, CAMK2A, PRKCQ, ALOX12 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.691E-04 | 1.587E-03 | MAPK10, PDGFRA, TBK1, FLT1, FGFR1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.504E-04 | 2.850E-03 | MAPK10, TBK1, CDK6, IKBKE |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 2.456E-04 | 2.141E-03 | MAPK10, GSK3B, TBK1, IKBKE |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 4.501E-04 | 3.335E-03 | PDGFRA, CDK6, CAMK2A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 4.726E-04 | 3.335E-03 | CAMK1D, ROCK2, CAMK2A, CAMKK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.921E-04 | 3.335E-03 | RET, PDGFRA, FGFR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 5.833E-04 | 3.530E-03 | PDGFRA, CDK6, FGFR1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 6.077E-04 | 3.530E-03 | MAPK10, GSK3B, JAK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.205E-03 | 5.879E-03 | ROCK2, CAMK2A, PTK2, FGFR1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.183E-03 | 5.879E-03 | MAPK10, GSK3B, TBK1, JAK3 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 8.538E-04 | 4.735E-03 | MAPK10, TBK1, JAK2, IKBKE |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.126E-03 | 5.879E-03 | PDGFRA, GSK3B, FGFR1 |
| 09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 1.463E-03 | 6.864E-03 | PDGFRA, ROCK2, PTK2, FGFR1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04622 | RIG-I-like receptor signaling pathway | 5.596E-04 | 3.530E-03 | MAPK10, TBK1, IKBKE |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 2.123E-03 | 8.932E-03 | ACHE, CAMK2A, JAK2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.861E-03 | 8.411E-03 | MAPK10, TBK1, IKBKE |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 2.016E-03 | 8.783E-03 | MAPK10, GSK3B, PRKCQ |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Polycythemia vera | D45 | JAK2; |
| I00-I99: Diseases of the circulatory system | Peripheral arterial occlusive disease | I73.9 | FGFR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PDGFRA; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | FLT1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | JAK2; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | JAK2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Renal transplantation | D89.8 | JAK2; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | FGFR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | JAK2; |
| C00-D49: Neoplasms | Myeloproliferative disorder | C94.6 | JAK2; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| NA: NA | Myeloproliferative neoplasm | NA | JAK2; |
| H00-H59: Diseases of the eye and adnexa | Exudative age-related macular degeneration | H35.3 | FLT1; |
| H00-H59: Diseases of the eye and adnexa | Neovascular age-related macular degeneration | H35.3 | FLT1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTK2; FGFR1; ACHE; FLT1; TNK2; JAK2; RET; GSK3B; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | PDGFRA; |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | PDGFRA; |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | FGFR1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | FLT1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | PDGFRA; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | ALK-positive advanced or metastatic NSCLC | C33, C34 | ROS1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; GSK3B; |
| I00-I99: Diseases of the circulatory system | Severe coronary heart disease | I25.1 | FGFR1; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | FLT1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2A; ROCK2; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | FLT1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Renal cancer | C64 | FLT1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2A; ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| P00-P96: Certain conditions originating in the perinatal period | Central nervous system injury | P11.9 | MAPK10; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | PDGFRA; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | FLT1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | IKBKE; |
| C00-D49: Neoplasms | Breast cancer | C50 | JAK2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; RET; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Anemia | D50-D64 | JAK2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PRKCQ; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PTK2; FGFR1; PDGFRA; MELK; RET; ROS1; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | RET; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | FGFR1; |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | FLT1; |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2; MARK3; |
| I00-I99: Diseases of the circulatory system | Hereditary hemorrhagic telangiectasia | I78.0 | FLT1; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | JAK2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
